Seven Eight Capital’s Immunocore IMCR Stock Holding History

Seven Eight Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,793	Closed	-$434K	–	832
2024 Q2	$434K	Buy	+12,793	New	+$652K	0.05%	545

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Seven Eight Capital's IMCR Position: Q3 2024 in Review

Seven Eight Capital sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 12,793 shares — an estimated $434K sold.

Seven Eight Capital first reported a position in IMCR in Q2 2024 and held it in 1 quarter. The position peaked at $434K in Q2 2024. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

Seven Eight Capital reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
Seven Eight Capital sold 12,793 Immunocore shares in Q3 2024, an estimated $434K.
Seven Eight Capital first reported a position in Immunocore in Q2 2024 and held it in 1 quarter.
Seven Eight Capital's Immunocore position peaked at $434K in Q2 2024.
130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.